In this paid-for advertorial for the Fall 2026 issue of DDW, Sampled shares insight on neurological disease with a genomics and multiomics lens. Genomic testing can identify drivers of neurological disease, but many variants remain difficult to interpret. Multiomics helps to close this gap by connecting genetic findings with… Read More
Dr James Heward, VP Functional Genomics at Nucleome Therapeutics, discusses what could be the missing link in the chain of causality from patient to target to drug. The fundamental question that stalks every drug discovery project is “will this drug fail?” Most do. There is no single reason for more than 90% of clinical… Read More
Genomics drug discovery company OutSee has been awarded funding through Innovate UK’s Investor Partnership Grant, jointly provided by Innovate UK and Empirical Ventures. The grant will enable OutSee to conduct a pilot study for a prototype target validation sub-system, designed for initial triage of potential drug targets… Read More
DDW Editor Reece Armstrong speaks to Dr Carlos Buesa, Founder and CEO of Oryzon Genomics, about epigenetic approaches to treating cancer and the company’s current journey within drug discovery and development. RA: Can an epigenetic approach help tackle aggressive cancers and those with poor prognoses? CB: Yes. Many aggressive cancers are… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
Alistair Henry, Executive Vice President Chief Scientific Officer at UCB, explains that various factors that are helping drive the development of T-cell engagers (TCEs). … Read More
Multiomics research services partner Novogene Europe has launched its Untargeted Metabolomics Service through its Cambridge Omics Centre. This new capability will help researchers across the UK and Europe to connect molecular data with biological function by adding metabolite-level insight to genomics, transcriptomics, microbiome and broader life science studies. Untargeted Metabolomics… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More
Diana Turner takes a look at drug discovery in India, a country making the shift from scale to innovation. While the Indian pharmaceuticals sector has long held a key global position… Read More
DDW Editor Reece Armstrong speaks to Michelle Carlson about overall advances in genomics and the integration of emerging technologies to create more drug discovery and development opportunities. RA: How is long-read sequencing enabling greater clinical research… Read More
OutSee has received a Discovery Award from the Longitude Prize on ALS, the genomics and drug discovery company has announced. The award will grant OutSee access to genomic data from 9,000 amyotrophic lateral sclerosis (ALS) patients, in addition to £100,000 ($134,000) in funding, supporting a research project… Read More
The Francis Crick Institute is set to house the UK’s first ancient DNA exhibition exploring human evolution and disease. The exhibition, set to open on 16 July 2026, is led by researchers at the Crick’s Ancient Genomics Laboratory. ‘We Go Way Back’ will uncover findings from… Read More
The world of drug discovery definitely kept us on our toes last year. Uncertainty in the market, not helped by the challenges created by changes in US drug pricing and tariffs, led to spending dips and nervousness throughout the sector. SLAS2026 is a key point in the… Read More
